Navigation Links
VIVUS Resubmits Qnexa NDA to the FDA
Date:10/17/2011

failure to obtain FDA or foreign authority clearances or approval; noncompliance with FDA or foreign regulations; and our dependence on the performance of our collaborative partners. As with any pharmaceutical in development, there are significant risks with development, regulatory approval, and commercialization of new products. There are no guarantees that our response to the FDA's CRL or the results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy and subsequent meetings and communications will be sufficient to satisfy the FDA's safety concerns, that the FDA will not require us to conduct any additional  prospective studies or retrospective observational studies, or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ending December 31, 2010, and periodic reports filed with the Securities and Exchange Commission.CONTACT:   VIVUS, Inc.Investor Relations:The Trout GroupTimothy E. MorrisBrian Korb Chief Financial Officerbkorb@troutgroup.com650-934-5200646-378-2923Media Relations:GolinHarrisSusan Brophysbrophy@golinharris.com312-729-4359
'/>"/>
SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
2. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
3. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
4. VIVUS Announces Promotion of Peter Tam to President
5. VIVUS to Present at Lazard Capital Markets Healthcare Conference
6. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
7. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
8. VIVUS Announces Sale of MUSE Assets to Meda
9. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
10. VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results
11. VIVUS to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), ... that its CGuard TM Embolic Prevention System reported positive ... Musialek , at the EuroPCR conference on May ... PARADIGM, an investigator-initiated P rospective evaluation of ... revascularization I n symptomatic and increased-risk asymptomatic carotid artery ...
(Date:5/22/2015)... Richmond Pharmacology is a ... a worldwide reputation for excellence in clinical trials. ... peer reviewed medical journals. Its officers are engaged ... discussions about rules for transparency and publication of ... , Clinical research is conducted worldwide, ...
(Date:5/21/2015)... CHICAGO , May 21, 2015 /PRNewswire-USNewswire/ ... lump along the side of his neck, ... and took a couple weeks off from ... didn,t go away.                               ... Rendino, 26, was referred to Michel ...
Breaking Medicine Technology:InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 3Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 4
... LAWRENCE, Mass., Nov. 9, 2010 NxStage Medical, ... manufacturer of innovative dialysis products, today announced that ... Brown, Chief Financial Officer, will participate in the ... Healthcare Summit Boston Harbor Hotel Boston, MATuesday, November ...
... ATLANTA, Nov. 9, 2010 The addition of ... associated with a rapid clinical response, improved function ... of adult rheumatoid arthritis (RA) patients reflecting those ... prior TNF-inhibitor use).  These positive clinical trial data ...
Cached Medicine Technology:NxStage Announces Fourth Quarter 2010 Investor Conference Schedule 2New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 2New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 3New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 4New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 5New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 6New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 7New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 8New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 9New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 10
(Date:5/25/2015)... New York, New York (PRWEB) May 25, 2015 ... and distributor of patented products, launches the Big Little ... ability to customize the perfect table that will suit ... reached a whopping revenue of $646 billion this past ... billion a year industry" says Scott J. Cooper, CEO ...
(Date:5/25/2015)... HomeCare is proud to announce that David Allerby, Co-Founder ... Iwamoto, Co-Founder & CMO, are Finalists for the Ernst ... Greater Los Angeles. The award is presented by EY ... and a personal commitment to their communities. , “Our ... of our organization,” said Co-Founder & CEO, David Allerby, ...
(Date:5/25/2015)... MA (PRWEB) May 25, 2015 A recent ... 2015 states 1,000 persons have died as a direct result ... 2014. This marks a 33% rise in overdose deaths attributed ... Charlie Baker, “This issue doesn’t care about geography. This issue ... This issue doesn’t care about class.” As the state of ...
(Date:5/25/2015)... May 25, 2015 Thousands of ... move forward in the federal multidistrict litigation now ... Texas. According to a Motion filed on May ... modify the Case Management Order pertaining to the ... things, the Motion seeks the adoption of a ...
(Date:5/25/2015)... CA (PRWEB) May 25, 2015 Join Fiona's ... a free two-hour instructional clinic. Irish National Player, Fiona ... and give them a taste of her coaching style. Fiona ... and Novato. Camps in Novato are at Lynwood Elmentary School ... , Novato High School - June 6th, 2015 - 1:00-3:00pm. ...
Breaking Medicine News(10 mins):Health News:Party Time - Top Officials Get Excited About World Patent Marketing's New Party Invention For Entertainment 2Health News:Party Time - Top Officials Get Excited About World Patent Marketing's New Party Invention For Entertainment 3Health News:24Hr HomeCare Co-Founders Named Finalists for EY Entrepreneur of the Year 2015 Awards 2Health News:Opioid Deaths Increase by 33 Percent Since 2012 in Mass. 2Health News:Federal DePuy Pinnacle Hip Lawsuits Move Forward, as Plaintiffs Seek to Modify Order Pertaining to Health Authorizations 2Health News:Federal DePuy Pinnacle Hip Lawsuits Move Forward, as Plaintiffs Seek to Modify Order Pertaining to Health Authorizations 3Health News:US Sports Camps and Nike Soccer Camps Offer Complimentary Instructional Clinic with Fiona's Soccer Camp 2
... and even old socks litter the shores of Lau Fau ... of the territory's oyster farming industry. From across the ... over Deep Bay, one of Hong Kong's most polluted stretches ... handed back to the Chinese, pollution is one of the ...
... having mood swings, and stays out late, then it could very ... ,The finding is based on a new research by ... on 107 adolescents with an average age of 17.98 years. ... were in love, and were experiencing intense romantic love, while the ...
... that around 350, 000 British senior citizens ... . , The major survey carried out by the ... by the Department of Health and Comic Relief is the first ... report titled: UK Study of Abuse and Neglect, found that 4 ...
... Schwarzenegger will call on British Prime Minister Tony Blair ... ,The California Governor wanted to work with ... warming, said a source close to Blair. ... speeches for when Mr Blair retires on June 27, ...
... Researchers at the University of Illinois at Chicago and ... silenced genes in patients who suffer from Neurodegenerative diseases ... stroke, certain cellular events take place that lead to ... group of enzymes called histone deacetylases can modulate gene ...
... restricted only to difficulty in walking on a uneven stretch, ... high heels are also making driving dangerous for over 12 ... footwear for driving and said that women are actually risking ... conducted by women's car insurance concern Sheilas Wheels revealed that ...
Cached Medicine News:Health News:Hong Kong Choked by Growing Pollution Problem 2Health News:Hong Kong Choked by Growing Pollution Problem 3Health News:Researchers Developing New Therapy to Re-activate Silenced Genes 2
Inquire...
Inquire...
Inquire...
... first time, the Integrated Cytometry Solution ... post-analytical solution coupled with complete LIS ... steps a sample undergoes - and ... one - it delivers a progressive ...
Medicine Products: